Stem cell study identifies enzyme with potential for cancer treatment

Research on how stem cells develop and differentiate in fruit flies has implications for human health

Scientists have found a new mechanism responsible for regulating stem cells in fruit flies, with possible implications for cancer therapies.

The study, published by University of Alberta biologists, identifies an inhibition mechanism of an enzyme called Myt1 kinase, which manages how stem cells develop and differentiate during organ development in fruit flies.

Shelagh Campbell
Shelagh Campbell

“In addition to furthering our understanding of developmental biology in fruit flies, this discovery is highly relevant to cancer research, where Myt1 is being scrutinized for its role in ‘checkpoint’ mechanisms that govern entry into mitosis,” said Shelagh Campbell, professor emerita in the Faculty of Science and member of the research team.

Campbell explained that these checkpoint mechanisms balance cell growth and differentiation as an organism develops, and are required for development of organs and tissues with appropriate size and function.

“This study shows how Myt1 regulates the cell cycle to allow cell differentiation, with defects in this process causing hyperproliferation and organ dysplasia,” said Campbell. “This greater understanding of Myt1 in fruit flies can be expected to benefit the development of effective cancer therapies with checkpoint inhibitor drugs.”

Even in organisms as diverse as humans and fruit flies, adult stem cells produce progenitor cells that differentiate into specialized types to regenerate intestinal cell walls, balancing cell loss by injury, infection and aging with new growth.

“Using fruit flies as a model, graduate student Reegan Willms discovered that loss of Myt1 caused hyperproliferation of intestinal stem cells and progenitor cells,” said Campbell. “Working with post-doctoral researcher Jie Zeng, Willms demonstrated that Myt1 is critical to inhibiting this process during normal cell growth.”

The study complements a recent collaboration with Gordon Chan and Armin Gamper in the U of A Faculty of Medicine & Dentistry. The findings also build on research by three PhD students over 20 years: Zhigang Jin, who created the original genetic model for studying Myt1; Joseph Ayeni, who characterized the biochemical mechanism; and Ramya Varadarajan, who first demonstrated that Myt1 could inhibit Cyclin A/Cdk1. The researchers are also contributing members of the Cancer Research Institute of Northern Alberta.

The study, Myt1 kinase couples mitotic cell cycle exit with differentiation in Drosophila, was published in Cell Reports.

| By Andrew Lyle

Folio, a Troy Media content provider partner, is the University of Alberta’s online publication.

© Troy Media


cancer treatment

The views, opinions and positions expressed by columnists and contributors are the author’s alone. They do not inherently or expressly reflect the views, opinions and/or positions of our publication.

You must be logged in to post a comment Login